In the following video, Motley Fool health-care analyst David Williamson highlights one pharmaceutical company that has no interest in organic growth. Valeant Pharmaceuticals is continuing its growth-through-acquisition strategy with the purchase of Obagi Medical Products , its 21st acquisition since 2011, for $344 million. David tells investors why this is a win for both parties, and how they should think of the investing thesis behind Valeant.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report " 3 Stocks That Will Help You Retire Rich " names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of.  Click here now  to keep reading.

The article Valeant Continues to Devour originally appeared on Fool.com.

David Williamson and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Investing in Emerging Markets

Learn to invest in a globalized world.

View Course »

What are Penny Stocks

The lucrative and dangerous world of penny stocks.

View Course »

Add a Comment

*0 / 3000 Character Maximum